SDC1在乳腺癌及其他肿瘤中作用的研究进展
Research Progress on the Role of SDC1 in Breast Cancer and Other Tumors
DOI: 10.12677/ACM.2022.12121726, PDF,   
作者: 吕莲秋*, 邓惠芳, 王 涵, 肖师晗, 聂文祥, 张 波#：华中科技大学同济医学院附属协和医院乳腺甲状腺外科，湖北 武汉
关键词: 乳腺癌；SDC1；治疗靶点；研究进展；Breast Cancer； SDC1； Therapeutic Target； Research Progress
摘要: 多配体蛋白聚糖-1 (SDC1)是硫酸乙酰肝素蛋白多糖(HSPG)的主要成员之一，具有调节代谢、转运和信息传递等功能。SDC1通过其胞外段硫酸乙酰肝素(HS)链，与多种配体结合，参与相应细胞信号的转导，在肿瘤发生发展中发挥着重要作用。乳腺癌是一种具有复杂异质性的恶性肿瘤，其发生发展与多种因素密切相关。尽管乳腺癌的诊断和治疗水平有明显提高，但它仍然是女性肿瘤死亡的第二大原因。因此，探知新的乳腺癌生物标志物和新的治疗靶标具有重要价值。多种研究发现SDC1在乳腺癌的诊断和治疗中具有重要意义，可作为乳腺癌潜在的分子标志物和治疗靶点。现就SDC1分子的结构、功能及其对乳腺癌的调控作用作一综述。
Abstract: Syndecan-1 (SDC1) is one of the main members of heparin sulfate proteoglycan (HSPG), which has functions of regulating metabolism, transporting and information transmission. As co-receptor, SDC1 combines with many ligands by the heparin sulfate on the extracellular domain, participates in cellular signal transduction and plays an important role in the occurrence and development of many malignant tumors. Breast cancer is a malignant tumor with complex heterogeneity, and its occurrence and development are closely related to many factors. Despite significant improvements in diagnosis and treatment of breast cancer, it remains the second leading cause of cancer death in women. Therefore, it is of great value to explore new biomarkers and therapeutic targets for breast cancer. Various studies have shown that SDC1 was of great significance in the diagnosis and treatment of breast cancer and could be used as a potential prognostic marker and therapeutic target for breast cancer. In this review, we focus on the structure, function and regulation of SDC1 in the breast cancer.
文章引用：吕莲秋, 邓惠芳, 王涵, 肖师晗, 聂文祥, 张波. SDC1在乳腺癌及其他肿瘤中作用的研究进展[J]. 临床医学进展, 2022, 12(12): 11980-11985. https://doi.org/10.12677/ACM.2022.12121726

参考文献

[1] Tuasha, N. and Petros, B. (2020) Heterogeneity of Tumors in Breast Cancer: Implications and Prospects for Prognosis and Therapeutics. Scientifica, 2020, Article ID: 4736091. [Google Scholar] [CrossRef] [PubMed]
[2] Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33. [Google Scholar] [CrossRef] [PubMed]
[3] Sarrazin, S., Lamanna, W.C. and Esko, J.D. (2011) Heparan Sulfate Pro-teoglycans. Cold Spring Harbor Perspectives in Biology, 3, Article ID: a004952. [Google Scholar] [CrossRef] [PubMed]
[4] Rangarajan, S., Richter, J.R., Richter, R.P., Bandari, S.K., Tripathi, K., Vlodavsky, I. and Sanderson, R.D. (2020) Heparanase-Enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression. Journal of Histochemistry & Cytochemistry, 68, 823-840. [Google Scholar] [CrossRef] [PubMed]
[5] Gharbaran, R. (2015) Advances in the Molecular Functions of Syndecan-1 (SDC1/CD138) in the Pathogenesis of Malignancies. Critical Reviews in Oncology/Hematology, 94, 1-17. [Google Scholar] [CrossRef] [PubMed]
[6] Parimon, T., Brauer, R., Schlesinger, S.Y., Xie, T., Jiang, D., Ge, L., Huang, Y., Birkland, T.P., Parks, W.C., Habiel, D.M., Hogaboam, C.M., Gharib, S.A., Deng, N., Liu, Z. and Chen, P. (2018) Syndecan-1 Controls Lung Tumorigenesis by Regulating miRNAs Packaged in Exosomes. The American Journal of Pathology, 188, 1094-1103. [Google Scholar] [CrossRef] [PubMed]
[7] Liu, W., Wang, Y., Zheng, J., Song, D., Zheng, S., Ren, L., Wang, Y., Yao, Y., Wang, Y., Liu, Y., Bai, R., Dong, J. and Liu, T. (2019) Syndecan-1 as an Independent Risk Factor for the Incidence of Adverse Cardiovascular Events in Patients Having Stage C and D Heart Failure with Non-Ischemic Dilated Cardiomyopathy. Clinica Chimica Acta, 490, 63-68. [Google Scholar] [CrossRef] [PubMed]
[8] Jaiswal, A.K., Sadasivam, M., Archer, N.K., Miller, R.J., Dillen, C.A., Ravipati, A., Park, P.W., Chakravarti, S., Miller, L.S. and Hamad, A.R.A. (2018) Syndecan-1 Regulates Psoriasiform Dermatitis by Controlling Homeostasis of IL-17- Producing γδ T Cells. The Journal of Immunology, 201, 1651-1661. [Google Scholar] [CrossRef] [PubMed]
[9] Bernfield, M., Götte, M., Park, P.W., Reizes, O., Fitzgerald, M.L., Lincecum, J. and Zako, M. (1999) Functions of Cell Surface Heparan Sulfate Proteoglycans. Annual review of biochemistry, 68, 729-777. [Google Scholar] [CrossRef] [PubMed]
[10] De Rossi, G. and Whiteford, J.R. (2013) Novel Insight into the Biological Functions of Syndecan Ectodomain Core Proteins. Biofactors, 39, 374-382. [Google Scholar] [CrossRef] [PubMed]
[11] Maday, S., Anderson, E., Chang, H.C., Shorter, J., Satoh, A., Sfakianos, J., Fölsch, H., Anderson, J.M., Walther, Z. and Mellman, I. (2008) A PDZ-Binding Motif Controls Basolateral Targeting of Syndecan-1 along the Biosynthetic Pathway in Polarized Epithelial Cells. Traffic, 9, 1915-1924. [Google Scholar] [CrossRef] [PubMed]
[12] Jung, O., Trapp-Stamborski, V., Purushothaman, A., Jin, H., Wang, H., Sanderson, R.D. and Rapraeger, A.C. (2016) Heparanase-Induced Shedding of Syndecan-1/CD138 in Myeloma and Endothelial Cells Activates VEGFR2 and an Invasive Phenotype: Prevention by Novel Synstatins. Oncogenesis, 5, e202. [Google Scholar] [CrossRef] [PubMed]
[13] Chakravarti, R., Sapountzi, V. and Adams, J.C. (2005) Functional Role of Syndecan-1 Cytoplasmic V Region in Lamellipodial Spreading, Actin Bundling, and Cell Migration. Molecular Biology of the Cell, 16, 3678-3691. [Google Scholar] [CrossRef] [PubMed]
[14] Alexopoulou, A.N., Multhaupt, H.A. and Couchman, J.R. (2007) Syndecans in Wound Healing, Inflammation and Vascular Biology. The International Journal of Biochemistry & Cell Biology, 39, 505-528. [Google Scholar] [CrossRef] [PubMed]
[15] Zhang, L., David, G. and Esko, J.D. (1995) Repetitive Ser-Gly Sequences Enhance Heparan Sulfate Assembly in Proteoglycans. Journal of Biological Chemistry, 270, 27127-27135. [Google Scholar] [CrossRef] [PubMed]
[16] Mulloy, B., Lever, R. and Page, C.P. (2017) Mast Cell Glycosaminoglycans. Glycoconjugate Journal, 34, 351-361. [Google Scholar] [CrossRef] [PubMed]
[17] Bertrand, J. and Bollmann, M. (2019) Soluble Syndecans: Bi-omarkers for Diseases and Therapeutic Options. British Journal of Pharmacology, 176, 67-81. [Google Scholar] [CrossRef] [PubMed]
[18] Derksen, P.W., Keehnen, R.M., Evers, L.M., Van Oers, M.H., Spaargaren, M. and Pals, S.T. (2002) Cell Surface Proteoglycan Syndecan-1 Mediates Hepatocyte Growth Factor Binding and Promotes Met Signaling in Multiple Myeloma. Blood, 99, 1405-1410. [Google Scholar] [CrossRef] 
[19] Moreaux, J., Sprynski, A.C., Dillon, S.R., Mahtouk, K., Jourdan, M., Ythier, A., Moine, P., Robert, N., Jourdan, E., Rossi, J.F. and Klein, B. (2009) APRIL and TACI Interact with Syndecan-1 on the Surface of Multiple Myeloma Cells to form an Essential Survival Loop. European Journal of Hae-matology, 83, 119-129. [Google Scholar] [CrossRef] [PubMed]
[20] Khotskaya, Y.B., Dai, Y., Ritchie, J.P., MacLeod, V., Yang, Y., Zinn, K. and Sanderson, R.D. (2009) Syndecan-1 Is Required for Robust Growth, Vascularization, and Me-tastasis of Myeloma Tumors in Vivo. Journal of Biological Chemistry, 284, 26085-26095. [Google Scholar] [CrossRef] 
[21] Wu, Y.H., Yang, C.Y., Chien, W.L., Lin, K.I. and Lai, M.Z. (2012) Removal of Syndecan-1 Promotes TRAIL-Induced Apoptosis in Myeloma Cells. The Journal of Immunology, 188, 2914-2921. [Google Scholar] [CrossRef] [PubMed]
[22] Purushothaman, A., Uyama, T., Kobayashi, F., Yamada, S., Sugahara, K., Rapraeger, A.C. and Sanderson, R.D. (2010) Heparanase-Enhanced Shedding of Syndecan-1 by Myeloma Cells Promotes Endothelial Invasion and Angiogenesis. Blood, 115, 2449-2457. [Google Scholar] [CrossRef] [PubMed]
[23] Francescone, R.A., Scully, S., Faibish, M., Taylor, S.L., Oh, D., Moral, L., Yan, W., Bentley, B. and Shao, R. (2011) Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma. Journal of Biological Chemistry, 286, 15332-15343. [Google Scholar] [CrossRef] 
[24] Yoshida, Y., Kurokawa, T., Nishikawa, Y., Orisa, M., Kleinman, H.K. and Kotsuji, F. (2008) Laminin-1-Derived Scrambled Peptide AG73T Disaggregates Laminin-1-Induced Ovarian Cancer Cell Spheroids and Improves the Efficacy of Cisplatin. International Journal of Oncology, 32, 673-681. [Google Scholar] [CrossRef] 
[25] Ramani, V.C. and Sanderson, R.D. (2014) Chemotherapy Stimulates Syndecan-1 Shedding: A Potentially Negative Effect of Treatment That May Promote Tumor Relapse. Matrix Biology, 35, 215-222. [Google Scholar] [CrossRef] [PubMed]
[26] Ramani, V.C., Yang, Y., Ren, Y., Nan, L. and Sanderson, R.D. (2011) Heparanase Plays a Dual Role in Driving Hepatocyte Growth Factor (HGF) Signaling by Enhancing HGF Ex-pression and Activity. Journal of Biological Chemistry, 286, 6490-6499. [Google Scholar] [CrossRef] 
[27] Wang, X., Zuo, D., Chen, Y., Li, W., Liu, R., He, Y., Ren, L., Zhou, L., Deng, T., Wang, X., Ying, G. and Ba, Y. (2014) Shed Syndecan-1 Is Involved in Chemotherapy Resistance via the EGFR Pathway in Colorectal Cancer. British Journal of Cancer, 111, 1965-1976. [Google Scholar] [CrossRef] [PubMed]
[28] Yu, L., Xu, H., Zhang, S., Chen, J. and Yu, Z. (2020) SDC1 Promotes Cisplatin Resistance in Hepatic Carcinoma Cells via PI3K-AKT Pathway. Human Cell, 33, 721-729. [Google Scholar] [CrossRef] [PubMed]
[29] Alexander, C.M., Reichsman, F., Hinkes, M.T., Lincecum, J., Becker, K.A., Cumberledge, S. and Bernfield, M. (2000) Syndecan-1 Is Required for Wnt-1-Induced Mammary Tumorigenesis in Mice. Nature Genetics, 25, 329-332. [Google Scholar] [CrossRef] [PubMed]
[30] Maeda, T., Desouky, J. and Friedl, A. (2006) Syndecan-1 Expression by Stromal Fibroblasts Promotes Breast Carcinoma Growth in Vivo and Stimulates Tumor Angiogenesis. Oncogene, 25, 1408-1412. [Google Scholar] [CrossRef] [PubMed]
[31] Sun, H., Berquin, I.M., Owens, R.T., O’Flaherty, J.T. and Edwards, I.J. (2008) Peroxisome Proliferator-Activated Receptor Gamma-Mediated Up-Regulation of Syndecan-1 by n-3 Fatty Acids Promotes Apoptosis of Human Breast Cancer Cells. Cancer Research, 68, 2912-2919. [Google Scholar] [CrossRef] 
[32] Vuoriluoto, K., Högnäs, G., Meller, P., Lehti, K. and Ivaska, J. (2011) Syndecan-1 and -4 Differentially Regulate Oncogenic K-ras Dependent Cell Invasion into Collagen through α2β1 Integrin and MT1-MMP. Matrix Biology, 30, 207-217. [Google Scholar] [CrossRef] [PubMed]
[33] Götte, M., Kersting, C., Ruggiero, M., Tio, J., Tulusan, A.H., Kiesel, L. and Wülfing, P. (2006) Predictive Value of Syndecan-1 Expression for the Response to Neoadjuvant Chem-otherapy of Primary Breast Cancer. Anticancer Research, 26, 621-627.
[34] Pradella, D., Naro, C., Sette, C. and Ghigna, C. (2017) EMT and Stemness: Flexible Processes Tuned by Alternative Splicing in Development and Cancer Progression. Molecular Cancer, 16, Article No. 8. [Google Scholar] [CrossRef] [PubMed]
[35] Orecchia, P., Conte, R., Balza, E., Petretto, A., Mauri, P., Mingari, M.C. and Carnemolla, B. (2013) A Novel Human Anti-Syndecan-1 Antibody Inhibits Vascular Maturation and Tumour Growth in Melanoma. European Journal of Cancer, 49, 2022-2033. [Google Scholar] [CrossRef] [PubMed]
[36] Macaulay, V.M., O’Byrne, K.J., Saunders, M.P., Braybrooke, J.P., Long, L., Gleeson, F., Mason, C.S., Harris, A.L., Brown, P. and Talbot, D.C. (1999) Phase I Study of Intrapleural Batimastat (BB-94), a Matrix Metalloproteinase Inhibitor, in the Treatment of Malignant Pleural Effusions. Clinical Cancer Research, 5, 513-520.
[37] Remacle, A.G., Golubkov, V.S., Shiryaev, S.A., Dahl, R., Stebbins, J.L., Chernov, A.V., Cheltsov, A.V., Pellecchia, M. and Strongin, A.Y. (2012) Novel MT1-MMP Small-Molecule Inhibitors Based on Insights into Hemopexin Domain Function in Tumor Growth. Cancer Research, 72, 2339-2349. [Google Scholar] [CrossRef] 
[38] Nguyen, T.L., Grizzle, W.E., Zhang, K., Hameed, O., Siegal, G.P. and Wei, S. (2013) Syndecan-1 Overexpression Is Associated with Nonluminal Subtypes and Poor Prognosis in Advanced Breast Cancer. American Journal of Clinical Pathology, 140, 468-474. [Google Scholar] [CrossRef] 

为你推荐